Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: PTSC has considrable leverage over TPL

TPL is constrained by the passed resolutions of the Management Committee of PDS whether they acquiesced or not.

TPL owes PTSC in the region of $2,000,000, part of which is secured against licensing revenues received by PDS.

Rather than "hemoraging(sic) cash", PTSC had sufficient to fund operations for the next twelve months, and that was before the CDX4 news.

The JV will continue, but with even closer scrutiny by PTSC, for the simple reason that it makes absolutely no sense for both patent owners to chase the same alleged infringers, in my very humble opinion, nor would it be cost effective to independently defend non-infringement claims through the court.

Who gets Henneman, for USPTO work, for example?

The JV was the only way forward, and remains the only way forward, with united ownership of the patents.

.

.

.

Be well

Share
New Message
Please login to post a reply